{"organizations": [], "uuid": "3b21e9c628cd309d56dd18b8dd830ee1b1d72c18", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180130.html", "section_title": "Archive News &amp; Video for Tuesday, 30 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vical-announces-restructuring-to-f/brief-vical-announces-restructuring-to-focus-resources-on-hsv-2-and-antifungal-clinical-programs-idUSASB0C331", "country": "US", "domain_rank": 408, "title": "BRIEF-Vical Announces Restructuring To Focus Resources On Hsv-2 And Antifungal Clinical Programs", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T05:45:00.000+02:00", "replies_count": 0, "uuid": "3b21e9c628cd309d56dd18b8dd830ee1b1d72c18"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vical-announces-restructuring-to-f/brief-vical-announces-restructuring-to-focus-resources-on-hsv-2-and-antifungal-clinical-programs-idUSASB0C331", "ord_in_thread": 0, "title": "BRIEF-Vical Announces Restructuring To Focus Resources On Hsv-2 And Antifungal Clinical Programs", "locations": [], "entities": {"persons": [{"name": "antifu", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "vical", "sentiment": "negative"}, {"name": "vical inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Vical Inc:\n* VICAL ANNOUNCES RESTRUCTURING TO FOCUS RESOURCES ON HSV-2 AND ANTIFUNGAL CLINICAL PROGRAMS\n* VICAL INC - ‍RESTRUCTURING INCLUDES A REDUCTION IN STAFF OF APPROXIMATELY 54%, FROM 74 TO 34 EMPLOYEES​\n* VICAL INC - ‍COMPANY IS TERMINATING ALL ACTIVITIES RELATED TO ASP0113 PROGRAM LICENSED TO ASTELLAS PHARMA​\n* VICAL INC - ‍BELIEVES ITS CURRENTLY AVAILABLE CASH AND INVESTMENTS WILL BE ADEQUATE TO FUND OPERATIONS AT LEAST THROUGH 2019​\n* VICAL INC - ‍RESTRUCTURING TO CONSERVE CAPITAL AND TO FOCUS EFFORTS ON VL-2397 AND ON COMPLETING PHASE 2 HSV-2 CLINICAL TRIAL​\n* VICAL INC - ‍EXPECTS TO REPORT THAT IT ENDED 2017 WITH CASH AND INVESTMENTS OF APPROXIMATELY $60 TO $65 MILLION​\n* VICAL INC - ‍CASH BURN FOR 2017 IS EXPECTED TO BE AT LOW END OF VICAL‘S GUIDANCE OF $8 TO $11 MILLION​\n* VICAL INC - ‍EXPECTS TO INCUR PERSONNEL-RELATED RESTRUCTURING CHARGES OF APPROXIMATELY $1.1 MILLION IN Q1 OF 2018​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-31T05:45:00.000+02:00", "crawled": "2018-01-31T16:36:48.002+02:00", "highlightTitle": ""}